{
    "2019-09-30": [
        [
            {
                "time": "2018-01-02",
                "original_text": "ROSEN, A GLOBALLY RECOGNIZED LAW FIRM, Reminds Novartis AG Investors of Important Deadline in Securities Class Action First Filed by the Firm – NVS",
                "features": {
                    "keywords": [
                        "Novartis",
                        "class action",
                        "investors",
                        "deadline"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2019-04-15",
                "original_text": "CVS pulls Zantac and its generic brand over possible cancer link",
                "features": {
                    "keywords": [
                        "CVS",
                        "Zantac",
                        "cancer",
                        "generic brand"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "retail"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2017-11-30",
                "original_text": "Roche's (RHHBY) Rituxan Receives FDA Nod for Label Expansion",
                "features": {
                    "keywords": [
                        "Roche",
                        "Rituxan",
                        "FDA",
                        "label expansion"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-02-20",
                "original_text": "CBMG: Initiating Coverage of Cellular Biomedicine Group; Multiple Cell-Based Therapies to Treat Cancer and Degenerative Diseases…",
                "features": {
                    "keywords": [
                        "CBMG",
                        "Cellular Biomedicine Group",
                        "cell-based therapies",
                        "cancer",
                        "degenerative diseases"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}